Arq. Bras. Cardiol. 2021; 117(4): 782-844

Update of the Brazilian Guideline for Familial Hypercholesterolemia – 2021

Maria Cristina de Oliveira Izar ORCID logo , Viviane Zorzanelli Rocha Giraldez ORCID logo , Adriana Bertolami ORCID logo , Raul Dias dos Santos Filho ORCID logo , Ana Maria Lottenberg ORCID logo , Marcelo Heitor Vieira Assad ORCID logo , José Francisco Kerr Saraiva ORCID logo , Ana Paula M. Chacra ORCID logo , Tania L. R. Martinez ORCID logo , Luciana Ribeiro Bahia ORCID logo , Francisco Antonio Helfenstein Fonseca ORCID logo , Andre Arpad Faludi, Andrei C. Sposito ORCID logo , Antônio Carlos Palandri Chagas, Cinthia Elim Jannes, Cristiane Kovacs Amaral, Daniel Branco de Araújo ORCID logo , Dennys Esper Cintra ORCID logo , Elaine dos Reis Coutinho ORCID logo , Fernando Cesena ORCID logo , Hermes Toros Xavier, Isabela Cardoso Pimentel Mota ORCID logo , Isabela de Carlos Back Giuliano ORCID logo , José Rocha Faria Neto ORCID logo , Juliana Tieko Kato ORCID logo , Marcelo Chiara Bertolami ORCID logo , Marcio Hiroshi Miname, Maria Helane Costa Gurgel Castelo ORCID logo , Maria Sílvia Ferrari Lavrador, Roberta Marcondes Machado, Patrícia Guedes de Souza, Renato Jorge Alves, Valeria Arruda Machado, Wilson Salgado Filho

DOI: 10.36660/abc.20210788

Introduction

Familial hypercholesterolemia (FH) is a common genetic cause of premature coronary artery disease (CAD), especially myocardial infarction, related to lifetime exposure to high concentrations of low-density lipoprotein cholesterol (LDL-C). It is a severe form of genetic dyslipidemia in which approximately 85% of men and 50% of women may experience a coronary event before 65 years of age if not properly treated.

FH is considered a public health problem because of the high prevalence (approximately 1:200-300 in the general population) and the association with early CAD. Reduced life expectancy was also observed in several families. In addition, nearly 200,000 people die each year worldwide from early heart attacks due to the disease, which could be prevented with appropriate treatments. If not treated, men and women with heterozygous FH will develop CAD before the ages of 55 and 60 years, respectively. Homozygotes, in turn, commonly develop CAD very early in life and, if not treated, may die before the age of 20. However, once the diagnosis is made and the treatment is initiated, the natural history of atherosclerotic disease can be changed.

[…]

Update of the Brazilian Guideline for Familial Hypercholesterolemia – 2021

Comments

Skip to content